A controlled trial with AHLG Behring: lack of effect on cadaveric renal graft survival.
To assess the effect of Pressimmune (AHLG-Behring), in high doses, (30 mg/kg/bdw for 21 days) as an adjuvant immunosuppressive drug a prospective, randomized controlled trial was carried out in 60 recipients of first time cadaveric renal allografts. There was no improvement in graft survival in the treatment group, and there was no steroid sparing. In the patients receiving Pressimmune, the T-lymphocyte count fell to about half pretransplant levels, and the first rejection episode occurred later than in the control patients, but eventually equally many kidneys were lost from rejection.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D000961:Antilymphocyte Serum / Q000009:adverse effects / Q000627:therapeutic use*; D002102:Cadaver; D002986:Clinical Trials as Topic; D005260:Female; D006084:Graft Rejection; D006085:Graft Survival; D006736:Horses; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000401:mortality / Q000628:therapy; D016030:Kidney Transplantation; D007958:Leukocyte Count; D008214:Lymphocytes; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000209:etiology; D013610:Tachycardia / Q000209:etiology
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents